An affordable autoinjector for all
Shawn Swanson is the CEO of MedsForAll. He completed his MS MSE in December of 2016, and since then has worked full time with the company. Shawn has been with the team since the beginning, and pursued this as a full time job directly after graduation. As the CEO, he has advanced the prototype, built a network of experienced advisors, and solidified the business plan.
Richard Lee is currently a Doctor of Pharmacy and a MBA Technology Entrepreneurship candidate at the University of Washington. Richard specializes in clinical trials, biomedical regulatory affairs, health economics, and global health. As a hospital clinician working for CHI Franciscan and community provider with Kaiser Permanente, he provides clinical guidance and strategic decision making related to healthcare and medical devices.
Ha Seung Chung is currently a Master’s student in Mechanical Engineering at the University of Washington. He received his BS in Mechanical Engineering from University of Washington in 2016, and has been working with MedsForAll since September 2015. His specialty is in mechanical product design.
Dr. Hansen is a research assistant professor of pharmacy. He received his Bachelor of Arts from Carroll College, and his Doctor of Pharmacy and Doctor of Philosophy from the University of Washington. Hansen is a fellow in the American College of Apothecaries, and a member of the International Society for Pharmacoeconomics and Outcomes Research and the Washington State Pharmacy Association. He was an Agency for Healthcare Research and Quality/UW K12 Patient Centered Outcomes Research Scholar, an ARCS Foundation Scholar, and was selected as a Distinguished Alumnus of the UW School of Pharmacy. He has served as a journal referee for “JAMA Internal Medicine,” “Pediatrics,” “Value in Health,” and “The Journal of Pain.” As an active pharmacy practitioner in a community practice setting, he applies his research skills in order to improve the practice of pharmacy.
Mr. Philips has over 30 years of pharmaceutical experience in the US and overseas with large, intermediate and start-up companies. His career includes experience with development and commercialization of both small molecules and biologic agents in a variety of sectors including: oncology, autoimmune diseases, cardiovascular disorders, viral diseases, and others. He spent the early part of his career with Bristol Myers and held senior positions at both Schering Plough (now Merck), and Bayer Pharmaceuticals. He was President at Cell Therapeutics, a company focused on new cancer therapies. Currently he is CEO of Kv1.3 Therapeutics, a company developing a first in class compound for a rare autoimmune disease. He also sits on the board of several private companies and serves as a Board advisor to others.
Mr. Downing is a Clinical Professor at the University Of Washington School Of Pharmacy in Seattle and Endowed Chair of the Institute for Innovative Pharmacy Practice. He and colleagues developed the first pharmacist-initiated contraception and immunization programs in the United States. In 2015 he co-wrote the first law in the United States that successfully recognizes and pays pharmacists as medical providers. Professor Downing has worked to improve the ability of pharmacists to provide needed clinical services in countries throughout the world – including India, Africa, Central & South America, Europe and the U.S. In order to accomplish this he works with academic institutions, pharmacy organizations, Ministries of Health, policy makers, health commissions and patient advocacy organizations.
Mr. Hammond is the principal consultant at Hammond Clinical Trial Consulting, LLC where his practice focuses on regulatory issues associated with research, development and FDA requirements that apply to bio-medical and health products. Mr. Hammond holds an MS in Biomedical Regulatory Affairs and has an extensive background in medical research. He provides advice to early stage and established biomedical product companies on regulatory issues across the product lifecycle, from bench top to clinical research, FDA pre-market requirements, labeling, and promotion and advertising. A key aspect of his practice focuses on working with companies creating Lab Developed Tests (LDTs) and helping those groups maneuver the changing FDA regulations. David also holds a faculty position in the University of Washington School of Pharmacy's Biomedical Regulatory Affairs program and is Director of the Clinical Research program.
Mr. Shoemaker is the Chief of Staff for Clinical Operations and Market Integration within the medical group of Kaiser Permanente Washington. He brings over 11 years of experience in the healthcare industry where he's held various leadership roles in an academic medical center, community health center, large regional health plan and now Kaiser Permanente Washington. In addition, Josh has extensive experience working with, piloting and advising startup companies. Josh supports the MedsForAll team in strategy, market and business development, customer value mapping, and feedback on how to navigate large companies with complex decision-processes.
Andy Stergachis, PhD, BPharm, is a Professor of Pharmacy and Global Healths, Director of the Global Medicines Program, and Associate Dean for Research, Graduate Studies and New Initiatives, School of Pharmacy, University of Washington (UW). In 1999, American Druggist selected him as one of the most influential pharmacists in the U.S. In 2013, the Washington State Pharmacy Association selected him as Pharmacists of the Year. In the private sector, he provided corporate leadership and focus for pharmacy during start-up, pre- and post-launch of drugstore.com from 1998-2002, where he served as Vice President & Chief Pharmacist.
He has served as Chairman of the UW’s Department of Pharmacy and the Department of Pathobiology, and Associate Dean of the School of Public Health. He is author of 151 peer-reviewed publications and serves as Editor-in- Chief of the Journal of the American Pharmacists Association. His global drug safety research and training activities involve strengthening pharmacy and
pharmacovigilance systems in low- and middle-income countries. Dr. Stergachis is an elected member of the
National Academy of Medicine and is a Fellow of the American Pharmacists Association and of the International Society for Pharmacoepidemiology.
EpiForAll won the $5,000 prize and an additional $2,500 for being the “Best Idea with Global Reach.”
$15,000 Grand Prize winner: EpiForAll creates Affordable EpiPen alternatives
The grand prize winner, EpiForAll, is an affordable EpiPen alternative for kids and families to combat the rising cost and accessibility of current market options.
MedsForAll receives 2017 SVP Fast Pitch Grow50 Consoritum Award and Lane Powell in-kind legal services award.
Students at the University of Washington are using engineering skills to design new types of medical devices, potentially at far lower costs than what's on the market.
At the 2017 Seattle Health Innovators President’s Awards, MedsForAll received the President’s Award for innovation in Regulatory Science Innovation.